Cargando…
Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, whi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451651/ https://www.ncbi.nlm.nih.gov/pubmed/30968054 http://dx.doi.org/10.1093/ofid/ofz099 |
_version_ | 1783409196424757248 |
---|---|
author | Sansom, Sarah E Martin, Jonathan Adeyemi, Oluwatoyin Burke, Kerianne Winston, Crystal Markham, Sara Go, Benjamin Huhn, Gregory |
author_facet | Sansom, Sarah E Martin, Jonathan Adeyemi, Oluwatoyin Burke, Kerianne Winston, Crystal Markham, Sara Go, Benjamin Huhn, Gregory |
author_sort | Sansom, Sarah E |
collection | PubMed |
description | BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, which may limit recognition of steatosis. We evaluated steatosis rates by LB and transient elastography (TE) with controlled attenuation parameter (CAP) among HCV-infected and HIV/HCV-coinfected patients in a US clinic. METHODS: Patients with chronic HCV infection during pretreatment evaluation by LB (n = 421; December 2001 through May 2014) and TE with CAP (n = 1157; May 2016 through May 2017) were included. Fibrosis and steatosis rates by LB and TE with CAP were stratified by HCV versus HIV/HCV coinfection status. RESULTS: Steatosis was not reported in 26.1% of LBs. Moderate to severe steatosis (grade ≥S2) was detected more often with CAP than with LB (in 24.0% vs 11.4% of patients, respectively). Median CAP values were higher in patients with HCV monoinfection than in those with coinfection (230 vs 215.5 dB/m, respectively; P < .001). With TE, the rate of advanced fibrosis (values F3–F4) was higher in HCV monoinfection than in coinfection (25.9% vs 14.8%, respectively; P <.001). With both LB and TE, advanced fibrosis (F3–F4) was significantly associated with moderate to severe steatosis (S2–S3) in HCV monoinfection compared with HIV/HCV coinfection (33.3% vs 4.4%, respectively for LB [P = 0.003] and 36.0% vs 29.0% for TE [P = 0.008]). CONCLUSIONS: In patients with chronic HCV undergoing liver fibrosis staging, steatosis was detected more often with CAP than LB, with median CAP values higher in HCV monoinfection than HIV/HCV coinfection. Steatosis severity may be increasing in the modern HCV treatment era. |
format | Online Article Text |
id | pubmed-6451651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64516512019-04-09 Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic Sansom, Sarah E Martin, Jonathan Adeyemi, Oluwatoyin Burke, Kerianne Winston, Crystal Markham, Sara Go, Benjamin Huhn, Gregory Open Forum Infect Dis Major Article BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, which may limit recognition of steatosis. We evaluated steatosis rates by LB and transient elastography (TE) with controlled attenuation parameter (CAP) among HCV-infected and HIV/HCV-coinfected patients in a US clinic. METHODS: Patients with chronic HCV infection during pretreatment evaluation by LB (n = 421; December 2001 through May 2014) and TE with CAP (n = 1157; May 2016 through May 2017) were included. Fibrosis and steatosis rates by LB and TE with CAP were stratified by HCV versus HIV/HCV coinfection status. RESULTS: Steatosis was not reported in 26.1% of LBs. Moderate to severe steatosis (grade ≥S2) was detected more often with CAP than with LB (in 24.0% vs 11.4% of patients, respectively). Median CAP values were higher in patients with HCV monoinfection than in those with coinfection (230 vs 215.5 dB/m, respectively; P < .001). With TE, the rate of advanced fibrosis (values F3–F4) was higher in HCV monoinfection than in coinfection (25.9% vs 14.8%, respectively; P <.001). With both LB and TE, advanced fibrosis (F3–F4) was significantly associated with moderate to severe steatosis (S2–S3) in HCV monoinfection compared with HIV/HCV coinfection (33.3% vs 4.4%, respectively for LB [P = 0.003] and 36.0% vs 29.0% for TE [P = 0.008]). CONCLUSIONS: In patients with chronic HCV undergoing liver fibrosis staging, steatosis was detected more often with CAP than LB, with median CAP values higher in HCV monoinfection than HIV/HCV coinfection. Steatosis severity may be increasing in the modern HCV treatment era. Oxford University Press 2019-03-01 /pmc/articles/PMC6451651/ /pubmed/30968054 http://dx.doi.org/10.1093/ofid/ofz099 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Sansom, Sarah E Martin, Jonathan Adeyemi, Oluwatoyin Burke, Kerianne Winston, Crystal Markham, Sara Go, Benjamin Huhn, Gregory Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title | Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title_full | Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title_fullStr | Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title_full_unstemmed | Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title_short | Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic |
title_sort | steatosis rates by liver biopsy and transient elastography with controlled attenuation parameter in clinical experience of hepatitis c virus (hcv) and human immunodeficiency virus/hcv coinfection in a large us hepatitis clinic |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451651/ https://www.ncbi.nlm.nih.gov/pubmed/30968054 http://dx.doi.org/10.1093/ofid/ofz099 |
work_keys_str_mv | AT sansomsarahe steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT martinjonathan steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT adeyemioluwatoyin steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT burkekerianne steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT winstoncrystal steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT markhamsara steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT gobenjamin steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic AT huhngregory steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic |